公开(公告)号：US11583537B2

公开(公告)日：2023-02-21

申请号：US17026593

申请日：2020-09-21

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Dana Wolf

IPC: A61K31/541 ,  A61P31/12 ,  A61K31/517 ,  A61K31/522 ,  A61K31/675 ,  A61K31/7056

Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.

公开(公告)号：US20230038224A1

公开(公告)日：2023-02-09

申请号：US17816060

申请日：2022-07-29

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Dana Wolf

IPC: G01N33/569

Abstract: The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).